Your browser doesn't support javascript.
loading
Regulated induced proximity targeting chimeras-RIPTACs-A heterobifunctional small molecule strategy for cancer selective therapies.
Raina, Kanak; Forbes, Chris D; Stronk, Rebecca; Rappi, Jonathan P; Eastman, Kyle J; Zaware, Nilesh; Yu, Xinheng; Li, Hao; Bhardwaj, Amit; Gerritz, Samuel W; Forgione, Mia; Hundt, Abigail; King, Madeline P; Posner, Zoe M; Correia, Allison D; McGovern, Andrew; Puleo, David E; Chenard, Rebekka; Mousseau, James J; Vergara, J Ignacio; Garvin, Ethan; Macaluso, Jennifer; Martin, Michael; Bassoli, Kyle; Jones, Kelli; Garcia, Marco; Howard, Katia; Yaggi, Madeleine; Smith, Levi M; Chen, Jinshan M; Mayfield, Andrew B; De Leon, Cesar A; Hines, John; Kayser-Bricker, Katherine J; Crews, Craig M.
Afiliação
  • Raina K; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Forbes CD; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Stronk R; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Rappi JP; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Eastman KJ; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Zaware N; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Yu X; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Li H; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Bhardwaj A; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Gerritz SW; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Forgione M; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Hundt A; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • King MP; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Posner ZM; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Correia AD; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • McGovern A; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Puleo DE; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Chenard R; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Mousseau JJ; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Vergara JI; Department of Molecular, Cellular, & Developmental Biology, Yale University, New Haven, CT, USA.
  • Garvin E; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Macaluso J; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Martin M; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Bassoli K; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Jones K; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Garcia M; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Howard K; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Yaggi M; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Smith LM; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Chen JM; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Mayfield AB; Department of Molecular, Cellular, & Developmental Biology, Yale University, New Haven, CT, USA.
  • De Leon CA; Department of Molecular, Cellular, & Developmental Biology, Yale University, New Haven, CT, USA.
  • Hines J; Department of Molecular, Cellular, & Developmental Biology, Yale University, New Haven, CT, USA.
  • Kayser-Bricker KJ; Halda Therapeutics OpCo Inc, New Haven, CT, USA. Electronic address: kat.kayser-bricker@haldathera.com.
  • Crews CM; Department of Molecular, Cellular, & Developmental Biology, Yale University, New Haven, CT, USA; Department of Pharmacology, Yale University, New Haven, CT, USA; Department of Chemistry, Yale University, New Haven, CT, USA. Electronic address: craig.crews@yale.edu.
Cell Chem Biol ; 31(8): 1490-1502.e42, 2024 Aug 15.
Article em En | MEDLINE | ID: mdl-39116881
ABSTRACT
We describe a protein proximity inducing therapeutic modality called Regulated Induced Proximity Targeting Chimeras or RIPTACs heterobifunctional small molecules that elicit a stable ternary complex between a target protein (TP) selectively expressed in tumor cells and a pan-expressed protein essential for cell survival. The resulting co-operative protein-protein interaction (PPI) abrogates the function of the essential protein, thus leading to death selectively in cells expressing the TP. This approach leverages differentially expressed intracellular proteins as novel cancer targets, with the advantage of not requiring the target to be a disease driver. In this chemical biology study, we design RIPTACs that incorporate a ligand against a model TP connected via a linker to effector ligands such as JQ1 (BRD4) or BI2536 (PLK1) or CDK inhibitors such as TMX3013 or dinaciclib. RIPTACs accumulate selectively in cells expressing the HaloTag-FKBP target, form co-operative intracellular ternary complexes, and induce an anti-proliferative response in target-expressing cells.
Assuntos
Antineoplásicos; Proteínas de Ciclo Celular; Bibliotecas de Moléculas Pequenas; Humanos; Proteínas de Ciclo Celular/metabolismo; Proteínas de Ciclo Celular/antagonistas & inibidores; Bibliotecas de Moléculas Pequenas/química; Bibliotecas de Moléculas Pequenas/farmacologia; Bibliotecas de Moléculas Pequenas/síntese química; Antineoplásicos/farmacologia; Antineoplásicos/química; Antineoplásicos/síntese química; Neoplasias/tratamento farmacológico; Neoplasias/metabolismo; Neoplasias/patologia; Proliferação de Células/efeitos dos fármacos; Triazóis/química; Triazóis/farmacologia; Quinase 1 Polo-Like; Proteínas Serina-Treonina Quinases/metabolismo; Proteínas Serina-Treonina Quinases/antagonistas & inibidores; Azepinas/farmacologia; Azepinas/química; Proteínas Proto-Oncogênicas/metabolismo; Proteínas Proto-Oncogênicas/antagonistas & inibidores; Fatores de Transcrição/metabolismo; Fatores de Transcrição/antagonistas & inibidores; Indolizinas/química; Indolizinas/farmacologia; Linhagem Celular Tumoral; Compostos Bicíclicos Heterocíclicos com Pontes/química; Compostos Bicíclicos Heterocíclicos com Pontes/farmacologia; Ligantes; Inibidores de Proteínas Quinases/farmacologia; Inibidores de Proteínas Quinases/química; Inibidores de Proteínas Quinases/síntese química; Compostos Heterocíclicos com 2 Anéis/farmacologia; Compostos Heterocíclicos com 2 Anéis/química; Compostos Heterocíclicos com 2 Anéis/síntese química; Proteínas Nucleares/metabolismo; Proteínas Nucleares/antagonistas & inibidores; Proteínas que Contêm Bromodomínio; Óxidos N-Cíclicos; Compostos de Piridínio
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas de Ciclo Celular / Bibliotecas de Moléculas Pequenas / Antineoplásicos Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas de Ciclo Celular / Bibliotecas de Moléculas Pequenas / Antineoplásicos Idioma: En Ano de publicação: 2024 Tipo de documento: Article